| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1039639626 |
| P356 | DOI | 10.1038/NATURE02460 |
| P698 | PubMed publication ID | 15034594 |
| P50 | author | Irving Weissman | Q884581 |
| P2093 | author name string | Robert C Robbins | |
| Amy J Wagers | |||
| Theo Kofidis | |||
| Julie L Christensen | |||
| Leora B Balsam | |||
| P2860 | cites work | Autologous bone-marrow stem-cell transplantation for myocardial regeneration | Q78761519 |
| Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells | Q24672061 | ||
| Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes | Q28209232 | ||
| Bone marrow cells regenerate infarcted myocardium | Q28210640 | ||
| Mobilized bone marrow cells repair the infarcted heart, improving function and survival | Q31002195 | ||
| Evidence that human cardiac myocytes divide after myocardial infarction | Q33950386 | ||
| Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction | Q36349782 | ||
| Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation | Q40611732 | ||
| Changing potency by spontaneous fusion. | Q40740330 | ||
| Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle | Q43567029 | ||
| Little evidence for developmental plasticity of adult hematopoietic stem cells | Q48491467 | ||
| Physiological migration of hematopoietic stem and progenitor cells. | Q52126942 | ||
| Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion | Q59064568 | ||
| Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart | Q64379356 | ||
| Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients | Q73106026 | ||
| Chimerism of the transplanted heart | Q77452324 | ||
| Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts | Q77885470 | ||
| P433 | issue | 6983 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 668-673 | |
| P577 | publication date | 2004-03-21 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium | |
| P478 | volume | 428 |
| Q58648634 | Q58648634 |
| Q35205665 | "Second-generation" stem cells for cardiac repair |
| Q37989880 | 'Hearts and bones': the ups and downs of 'plasticity' in stem cell biology. |
| Q26825049 | 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice |
| Q90573402 | 3D bioprinting for cardiovascular regeneration and pharmacology |
| Q36543846 | 7. Transplantation of undifferentiated, bone marrow-derived stem cells |
| Q41166315 | A 3-D cardiac muscle construct for exploring adult marrow stem cell based myocardial regeneration |
| Q33719810 | A Hyper-Crosslinked Carbohydrate Polymer Scaffold Facilitates Lineage Commitment and Maintains a Reserve Pool of Proliferating Cardiovascular Progenitors |
| Q37611644 | A Novel Human Tissue-Engineered 3-D Functional Vascularized Cardiac Muscle Construct |
| Q35762460 | A decade of discoveries in cardiac biology |
| Q28474773 | A plant-derived remedy for repair of infarcted heart |
| Q28299027 | A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow |
| Q37117849 | A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats |
| Q42738342 | A repair "kit" for the infarcted heart |
| Q35824092 | A role for chemistry in stem cell biology |
| Q92840144 | Absence of myocyte regeneration by mobilization of bone marrow stem cells after myocardial infarction |
| Q64084663 | Acellular Extracellular Matrix Bioscaffolds for Cardiac Repair and Regeneration |
| Q36655337 | Actions and therapeutic potential of G-CSF and GM-CSF in cardiovascular disease |
| Q37151499 | Activated c-Kit receptor in the heart promotes cardiac repair and regeneration after injury |
| Q34477403 | Adhesion proteins, stem cells, and arrhythmogenesis |
| Q27304355 | Adipose Tissue-Derived Mesenchymal Stromal Cells Protect Mice Infected with Trypanosoma cruzi from Cardiac Damage through Modulation of Anti-parasite Immunity |
| Q37698929 | Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review |
| Q33330259 | Adult bone marrow-derived cells do not acquire functional attributes of cardiomyocytes when transplanted into peri-infarct myocardium |
| Q33225563 | Adult bone marrow-derived cells: regenerative potential, plasticity, and tissue commitment |
| Q36904778 | Adult bone marrow-derived stem cells for organ regeneration and repair |
| Q47338717 | Adult skeletal muscle stem cells differentiate into endothelial lineage and ameliorate renal dysfunction after acute ischemia. |
| Q79390001 | Adult stem cell plasticity: introduction to the first issue of stem cell reviews |
| Q37779933 | Adult stem cells for cardiac tissue engineering |
| Q36842703 | Adult stem cells for cardiovascular diseases: the adipose tissue potential |
| Q35832764 | Adult stem cells--reprogramming neurological repair? |
| Q41906508 | Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy |
| Q50701050 | Advances in cardiovascular molecular imaging for tracking stem cell therapy. |
| Q33957120 | Aesthetic cardiology: adipose-derived stem cells for myocardial repair |
| Q37536177 | Allogeneic amniotic membrane-derived mesenchymal stromal cell transplantation in a porcine model of chronic myocardial ischemia |
| Q37310724 | Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. |
| Q42949554 | Amplification of coronary arteriogenic capacity of multipotent stromal cells by epidermal growth factor |
| Q35565809 | An emerging consensus on cardiac regeneration |
| Q30480151 | Angiomyogenesis for myocardial repair |
| Q34508351 | Animal models of cardiac disease and stem cell therapy |
| Q36512731 | Antiapoptotic effect of implanted embryonic stem cell-derived early-differentiated cells in aging rats after myocardial infarction |
| Q93089068 | Application of Bioengineered Materials in the Surgical Management of Heart Failure |
| Q38938530 | Arrhythmogenesis: a Roadblock to Cardiac Stem Cell Therapy. |
| Q51822210 | Artificial matrix helps neonatal cardiomyocytes restore injured myocardium in rats. |
| Q39514108 | At a crossroad: cell therapy for cardiac repair |
| Q46824683 | Autologous bone marrow-derived stem cells for ischemic heart failure: REGENERATE-IHD trial |
| Q34563950 | Autologous cardiomyotissue implantation promotes myocardial regeneration, decreases infarct size, and improves left ventricular function |
| Q40317182 | BMP-2 and FGF-2 synergistically facilitate adoption of a cardiac phenotype in somatic bone marrow c-kit+/Sca-1+ stem cells |
| Q39653342 | Bioactive scaffolds for engineering vascularized cardiac tissues |
| Q42488789 | Bioenergetic and functional consequences of stem cell-based VEGF delivery in pressure-overloaded swine hearts |
| Q37178066 | Bioengineering to enhance progenitor cell therapeutics |
| Q36163604 | Biological implications of cell fusion. |
| Q36596218 | Biology of bone marrow-derived endothelial cell precursors |
| Q36127860 | Biomaterial strategies to improve the efficacy of bone marrow cell therapy for myocardial infarction |
| Q26852224 | Biomaterials to enhance stem cell function in the heart |
| Q36737037 | Biomimetic approach to cardiac tissue engineering |
| Q37217388 | Blood-derived small Dot cells reduce scar in wound healing |
| Q95266751 | Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Improves Spinal Cord Function After Injury in Rats by Activating Autophagy |
| Q38531024 | Bone Marrow Therapies for Chronic Heart Disease |
| Q50946128 | Bone Marrow Very Small Embryonic-Like Stem Cells: New Generation of Autologous Cell Therapy Soon Ready for Prime Time? |
| Q42105273 | Bone Marrow-Derived Mesenchymal Stem Cells Improve Diabetic Neuropathy by Direct Modulation of Both Angiogenesis and Myelination in Peripheral Nerves |
| Q37783801 | Bone marrow and circulating stem/progenitor cells for regenerative cardiovascular therapy |
| Q36132019 | Bone marrow as a home of heterogenous populations of nonhematopoietic stem cells. |
| Q36012911 | Bone marrow as a source of circulating CXCR4+ tissue-committed stem cells |
| Q37826666 | Bone marrow cell injection for chronic myocardial ischemia: the past and the future |
| Q40348037 | Bone marrow cell transfer in acute myocardial infarction |
| Q53316434 | Bone marrow cell transplantation improves cardiac, autonomic, and functional indexes in acute anterior myocardial infarction patients (Cardiac Study). |
| Q33304156 | Bone marrow cells adopt the cardiomyogenic fate in vivo |
| Q33379564 | Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction |
| Q50770952 | Bone marrow cells differentiate into wound myofibroblasts and accelerate the healing of wounds with exposed bones when combined with an occlusive dressing. |
| Q33254416 | Bone marrow cells for cardiac regeneration and repair: current status and issues |
| Q43193969 | Bone marrow mesenchymal stem cells can differentiate and assume corneal keratocyte phenotype |
| Q26821783 | Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network |
| Q27006710 | Bone marrow mononuclear cells and acute myocardial infarction |
| Q42112337 | Bone marrow mononuclear stem cells transplanted in rat infarct myocardium improved the electrical conduction without evidence of proarrhythmic effects |
| Q37194005 | Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction. |
| Q28251098 | Bone marrow stem cell transplantation for cardiac repair |
| Q38166729 | Bone marrow-derived cell therapy in chagasic cardiac disease: a review of pre-clinical and clinical results |
| Q34103630 | Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair |
| Q37293770 | Bone marrow-derived cells can acquire cardiac stem cells properties in damaged heart |
| Q37138922 | Bone marrow-derived cells home to and regenerate retinal pigment epithelium after injury |
| Q28278074 | Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth |
| Q33202256 | Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation |
| Q38233057 | Bone marrow-derived mesenchymal cell differentiation toward myogenic lineages: facts and perspectives. |
| Q50653136 | Bone marrow-derived myofibroblasts contribute functionally to scar formation after myocardial infarction. |
| Q36804551 | Bone marrow-derived stem cell therapy in ischemic heart disease |
| Q36922408 | Bone marrow-derived stem cells in wound healing: a review |
| Q36844563 | Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study. |
| Q28591940 | CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice |
| Q42742614 | CD144 (VE-cadherin) is transiently expressed by fetal liver hematopoietic stem cells |
| Q34125508 | CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease |
| Q33927282 | CD34+ cells represent highly functional endothelial progenitor cells in murine bone marrow |
| Q37967719 | CD34-positive stem cells: in the treatment of heart and vascular disease in human beings |
| Q57951477 | COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133+ Bone Marrow Stem Cells to Placebo in Patients After Acute Myocardial Infarction and Left Ventricular Dysfunction: Study Rationale and Design |
| Q51724009 | CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. |
| Q34026068 | Calcification after myocardial infarction is independent of amniotic fluid stem cell injection |
| Q33213658 | Can a bone marrow cell contribute to organ regeneration? In vivo analysis using transgenic rats with reporter genes |
| Q38161754 | Can stem cells really regenerate the human heart? Use your noggin, dickkopf! Lessons from developmental biology |
| Q61958028 | Cardiac Cell Therapy: The Next (Re)Generation |
| Q34169758 | Cardiac Function, Perfusion, Metabolism, and Innervation following Autologous Stem Cell Therapy for Acute ST-Elevation Myocardial Infarction. A FINCELL-INSIGHT Sub-Study with PET and MRI. |
| Q36146340 | Cardiac Regeneration and Stem Cells. |
| Q41024149 | Cardiac Stem Cells for Myocardial Regeneration: They Are Not Alone |
| Q80751107 | Cardiac aid to the injured but not the elderly? |
| Q37371934 | Cardiac cell repair therapy: a clinical perspective |
| Q35144550 | Cardiac cell therapy: where we've been, where we are, and where we should be headed |
| Q37092180 | Cardiac cell-based therapy: cell types and mechanisms of actions |
| Q27303596 | Cardiac engraftment of genetically-selected parthenogenetic stem cell-derived cardiomyocytes |
| Q42859300 | Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart |
| Q34334027 | Cardiac progenitor cells and bone marrow-derived very small embryonic-like stem cells for cardiac repair after myocardial infarction |
| Q44325515 | Cardiac progenitor cells application in cardiovascular disease. |
| Q35928368 | Cardiac regeneration |
| Q26822619 | Cardiac regeneration therapy: connections to cardiac physiology |
| Q34617472 | Cardiac regeneration using pluripotent stem cells--progression to large animal models. |
| Q34643788 | Cardiac regenerative capacity and mechanisms |
| Q90082403 | Cardiac regenerative therapy: Many paths to repair |
| Q37253735 | Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease |
| Q91291231 | Cardiac repair and the putative role of stem cells |
| Q36349185 | Cardiac repair by embryonic stem-derived cells |
| Q33406980 | Cardiac repair with adult bone marrow-derived cells: the clinical evidence |
| Q24534652 | Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction |
| Q46146747 | Cardiac repair with thymosin β4 and cardiac reprogramming factors |
| Q35897332 | Cardiac specification of embryonic stem cells. |
| Q37766145 | Cardiac stem cell therapy and arrhythmogenicity: prometheus and the arrows of Apollo and Artemis |
| Q38040206 | Cardiac stem cell therapy: stemness or commitment? |
| Q36267790 | Cardiac stem cells and mechanisms of myocardial regeneration |
| Q37182776 | Cardiac stem cells and progenitors: developmental biology and therapeutic challenges. |
| Q36603788 | Cardiac stem cells: A promising treatment option for heart failure |
| Q35122190 | Cardiac stem/progenitor cells, secreted proteins, and proteomics |
| Q37869908 | Cardiac tissue engineering: a clinical perspective |
| Q41761869 | Cardiac tissue engineering: a reflection after a decade of hurry |
| Q37423133 | Cardiac tissue engineering: implications for pediatric heart surgery |
| Q37319214 | Cardiogenic differentiation and transdifferentiation of progenitor cells |
| Q80028254 | Cardiologists take heart from stem-cell treatment success |
| Q81386720 | Cardiology: solace for the broken-hearted? |
| Q47951585 | Cardiomyocyte Regeneration: A Consensus Statement |
| Q34725406 | Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction |
| Q37832530 | Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models |
| Q53468657 | Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase. |
| Q36309565 | Cardiomyocytes derived from stem cells |
| Q37002682 | Cardiomyogenic stem and progenitor cell plasticity and the dissection of cardiopoiesis |
| Q34698821 | Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines |
| Q42028739 | Cardiovascular Stem Cells in Regenerative Medicine: Ready for Prime Time? |
| Q41367762 | Cardiovascular repair with bone marrow-derived cells |
| Q53508391 | Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials. |
| Q33613197 | Cell fusion of bone marrow cells and somatic cell reprogramming by embryonic stem cells |
| Q42605371 | Cell memory-based therapy |
| Q37766153 | Cell therapy for acute myocardial infarction--where do we go from here? |
| Q38095938 | Cell therapy for cardiovascular diseases |
| Q27001159 | Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions |
| Q37776514 | Cell therapy for heart failure: the need for a new therapeutic strategy |
| Q38226693 | Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. |
| Q33295408 | Cell therapy in congestive heart failure |
| Q37388609 | Cell therapy with bone marrow cells for myocardial regeneration |
| Q37187645 | Cell tracking and therapy evaluation of bone marrow monocytes and stromal cells using SPECT and CMR in a canine model of myocardial infarction |
| Q35589728 | Cell tracking in cardiac repair: what to image and how to image. |
| Q37118515 | Cell transplantation for cardiac regeneration: where do we stand? |
| Q35932397 | Cell transplantation for myocardial regeneration: hype or reality? |
| Q53775191 | Cell transplantation in heart failure: where do we stand in 2016? |
| Q36667275 | Cell-based approaches for cardiac repair |
| Q35874249 | Cell-based myocardial repair: how should we proceed? |
| Q36277263 | Cell-based therapies and imaging in cardiology |
| Q36176132 | Cell-based therapy for prevention and reversal of myocardial remodeling |
| Q38068940 | Cell-based vasculogenic studies in preclinical models of chronic myocardial ischaemia and hibernation. |
| Q38859871 | Cellular Therapy for Heart Failure. |
| Q35847332 | Cellular approaches to tissue repair in cardiovascular disease: the more we know, the more there is to learn |
| Q36669952 | Cellular cardiomyoplasty by catheter-based infusion of stem cells in clinical settings |
| Q39410733 | Cellular mechanisms underlying cardiac engraftment of stem cells. |
| Q37016337 | Cellular therapies for heart disease: unveiling the ethical and public policy challenges |
| Q37687140 | Cellular therapy for repair of cardiac damage after acute myocardial infarction |
| Q37583950 | Challenges in cardiac tissue engineering |
| Q28083859 | Challenges in identifying the best source of stem cells for cardiac regeneration therapy |
| Q37731741 | Challenges in the translation of cardiovascular cell therapy |
| Q38059068 | Challenges measuring cardiomyocyte renewal |
| Q50634035 | Challenging the cardiac differentiation of bone marrow cells: a clinical perspective. |
| Q57072502 | Changing Metabolism in Differentiating Cardiac Progenitor Cells-Can Stem Cells Become Metabolically Flexible Cardiomyocytes? |
| Q38360697 | Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. |
| Q38669503 | Chasing c-Kit through the heart: Taking a broader view |
| Q54561747 | Chimerism and microchimerism of the human heart: evidence for cardiac regeneration. |
| Q43189856 | Circulating around the tissue: hematopoietic cell-based fusion versus transdifferentiation |
| Q37642130 | Circulating smooth muscle progenitor cells in atherosclerosis and plaque rupture: current perspective and methods of analysis. |
| Q38114986 | Clinical application of adult stem cells for therapy for cardiac disease |
| Q49029956 | Clinical impact of combined transplantation of autologous skeletal myoblasts and bone marrow mononuclear cells in patients with severely deteriorated ischemic cardiomyopathy |
| Q51897883 | Clonal Analysis Reveals a Common Progenitor for Endothelial, Myeloid, and Lymphoid Precursors in Umbilical Cord Blood |
| Q33777861 | Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction |
| Q46767299 | Closed-chest cell injections into mouse myocardium guided by high-resolution echocardiography |
| Q36127880 | Coculture with hematopoietic stem cells protects cardiomyocytes against apoptosis via paracrine activation of AKT |
| Q38926005 | Combination of miRNA499 and miRNA133 exerts a synergic effect on cardiac differentiation. |
| Q55053507 | Combining censored and uncensored data in a U-statistic: design and sample size implications for cell therapy research. |
| Q89488660 | Commentary: Alas, we are not yet zebrafish |
| Q53537945 | Comparison of cell therapy and cytokine therapy for functional repair in ischemic and nonischemic heart failure. |
| Q36853991 | Comparison of different adult stem cell types for treatment of myocardial ischemia |
| Q37714135 | Comparison of the proliferation, migration and angiogenic properties of human amniotic epithelial and mesenchymal stem cells and their effects on endothelial cells |
| Q33835210 | Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart |
| Q34243010 | Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration |
| Q50644699 | Connexin 40 promoter-based enrichment of embryonic stem cell-derived cardiovascular progenitor cells. |
| Q36406455 | Contemplating the bright future of stem cell therapy for cardiovascular disease |
| Q34717227 | Contribution of bone marrow-derived hematopoietic stem/progenitor cells to the generation of donor-marker⁺ cardiomyocytes in vivo. |
| Q37521994 | Contribution of human hematopoietic stem cells to liver repair. |
| Q35331907 | Convergence of normal stem cell and cancer stem cell developmental stage: Implication for differential therapies |
| Q45644333 | Cord blood cell therapy alters LV remodeling and cytokine expression but does not improve heart function after myocardial infarction in rats |
| Q53630947 | Coronary effluent from postconditioned hearts promotes survival of mesenchymal stem cells under hypoxia. |
| Q37731746 | Current perspectives on imaging cardiac stem cell therapy |
| Q35623878 | Current status of stem cell therapy in heart failure |
| Q27004753 | Current stem cell delivery methods for myocardial repair |
| Q53628210 | Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. |
| Q39032257 | Dating the Heart: Exploring Cardiomyocyte Renewal in Humans |
| Q34271595 | De novo myocardial regeneration: advances and pitfalls |
| Q34248666 | Delivery and tracking of therapeutic cell preparations for clinical cardiovascular applications. |
| Q42376285 | Delivery of biotinylated IGF-1 with biotinylated self-assembling peptides combined with bone marrow stem cell transplantation promotes cell therapy for myocardial infarction |
| Q43253690 | Design of a 3D aligned myocardial tissue construct from biodegradable polyesters |
| Q33713141 | Determination of the fate and contribution of ex vivo expanded human bone marrow stem and progenitor cells for bone formation by 2.3ColGFP. |
| Q33824505 | Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). |
| Q37455469 | Development of bioactive peptide amphiphiles for therapeutic cell delivery |
| Q34617338 | Diabetes and aging alter bone marrow contributions to tissue maintenance |
| Q35599232 | Diabetes irreversibly depletes bone marrow-derived mesenchymal progenitor cell subpopulations. |
| Q43272453 | Differential ability of somatic stem cells. |
| Q51867950 | Differential activity of bone marrow hematopoietic stem cell subpopulations for EPC development and ischemic neovascularization. |
| Q81123128 | Differential myocardial infarct repair with muscle stem cells compared to myoblasts |
| Q47575065 | Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats. |
| Q58816270 | Differentiation of circulating endothelial progenitor cells to a cardiomyogenic phenotype depends on E-cadherin |
| Q35236178 | Direct evaluation of myocardial viability and stem cell engraftment demonstrates salvage of the injured myocardium |
| Q42429956 | Direct intracardiac injection of umbilical cord-derived stromal cells and umbilical cord blood-derived endothelial cells for the treatment of ischemic cardiomyopathy. |
| Q36918318 | Do stem cells in the heart truly differentiate into cardiomyocytes? |
| Q29304005 | Donor Myocardial Infarction Impairs the Therapeutic Potential of Bone Marrow Cells by an Interleukin-1-Mediated Inflammatory Response |
| Q36814737 | Donor cell transplantation for myocardial disease: does it complement current pharmacological therapies? |
| Q47573004 | Donor mesenchymal stromal cells (MSCs) undergo variable cardiac reprogramming in vivo and predominantly co-express cardiac and stromal determinants after experimental acute myocardial infarction. |
| Q36898800 | Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy. |
| Q33403153 | Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy |
| Q37253137 | Dynamic Tracking of Injected Mesenchymal Stem Cells after Myocardial Infarction in Rats: A Serial 7T MRI Study. |
| Q50658526 | Effect of 5-Azacytidine: Evidence for Alteration of the Multipotent Ability of Mesenchymal Stem Cells |
| Q43270064 | Effect of 5-azacytidine induction duration on differentiation of human first-trimester fetal mesenchymal stem cells towards cardiomyocyte-like cells |
| Q46968356 | Effect of aging on the pluripotential capacity of human CD105+ mesenchymal stem cells |
| Q34062678 | Effect of disruption of Akt-1 of lin(-)c-kit(+) stem cells on myocardial performance in infarcted heart |
| Q41672231 | Effect of mHCN2 gene modification on chronotropic relevant receptors in BMSCs co-cultured with atrial myocytes |
| Q87345457 | Effects of Ca2+-activated potassium and inward rectifier potassium channel on the differentiation of endothelial progenitor cells from human peripheral blood |
| Q36371225 | Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction |
| Q82662237 | Effects of granulocyte-colony-stimulating factor on mobilization of bone-marrow-derived stem cells after myocardial infarction in humans |
| Q33590936 | Effects of stem cell therapy on left ventricular remodeling after acute myocardial infarction: a meta-analysis. |
| Q33607929 | Efficacy and safety of intracoronary autologous bone marrow-derived cell transplantation in patients with acute myocardial infarction: insights from randomized controlled trials with 12 or more months follow-up. |
| Q40139872 | Efficient transient genetic labeling of human CD34+ progenitor cells for in vivo application |
| Q35201621 | Embryonic stem cell-derived cardiomyocyte heterogeneity and the isolation of immature and committed cells for cardiac remodeling and regeneration |
| Q36995124 | Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions |
| Q80833914 | Embryonic stem cells pace the heart |
| Q36920724 | Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology |
| Q37974944 | Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves |
| Q28303395 | Endothelial progenitor cells: identity defined? |
| Q37325660 | Endothelial progenitor cells: implications for cardiovascular disease |
| Q34508414 | Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts |
| Q35747710 | Engineered myocardial tissues constructed in vivo using cardiomyocyte-like cells derived from bone marrow mesenchymal stem cells in rats |
| Q36804669 | Engineering stem cells for therapy |
| Q39848465 | Engraftment of mesenchymal stem cells into dystrophin-deficient mice is not accompanied by functional recovery |
| Q39864941 | Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy |
| Q36121810 | Enhanced angiogenic and cardiomyocyte differentiation capacity of epigenetically reprogrammed mouse and human endothelial progenitor cells augments their efficacy for ischemic myocardial repair |
| Q34055868 | Enhanced potency of cell-based therapy for ischemic tissue repair using an injectable bioactive epitope presenting nanofiber support matrix |
| Q50516456 | Enhanced therapeutic effects of mesenchymal stem cells on myocardial infarction by ischemic postconditioning through paracrine mechanisms in rats. |
| Q38930599 | Epicardium-Derived Heart Repair. |
| Q50868250 | Evaluating the role of autologous mesenchymal stem cell seeded on decellularized pericardium in the treatment of myocardial infarction: an animal study. |
| Q37273936 | Evidence that bone marrow cells do not contribute to the alveolar epithelium |
| Q40018932 | Evolution of the c-kit-positive cell response to pathological challenge in the myocardium |
| Q89530712 | Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1/M2 polarization |
| Q64108486 | Exosomes Derived From Pericytes Improve Microcirculation and Protect Blood-Spinal Cord Barrier After Spinal Cord Injury in Mice |
| Q37675908 | Exosomes Secreted from Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Prevent Osteonecrosis of the Femoral Head by Promoting Angiogenesis |
| Q59795422 | Exosomes: Basic Biology and Technological Advancements Suggesting Their Potential as Ischemic Heart Disease Therapeutics |
| Q45831019 | Expansion of Umbilical Cord Blood Aldehyde Dehydrogenase Expressing Cells Generates Myeloid Progenitor Cells that Stimulate Limb Revascularization |
| Q28073078 | Exploring pericyte and cardiac stem cell secretome unveils new tactics for drug discovery |
| Q50736830 | Expression of green fluorescent protein impairs the force-generating ability of isolated rat ventricular cardiomyocytes. |
| Q38195538 | Extra- and intracellular factors regulating cardiomyocyte proliferation in postnatal life. |
| Q36942196 | FDG-PET reveals improved cardiac regeneration and attenuated adverse remodelling following Sitagliptin + G-CSF therapy after acute myocardial infarction |
| Q33842934 | FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. |
| Q37228759 | Features of cardiomyocyte proliferation and its potential for cardiac regeneration. |
| Q27309113 | Fetal myocardium in the kidney capsule: an in vivo model of repopulation of myocytes by bone marrow cells |
| Q37608231 | Fetal skin wound healing. |
| Q37120596 | Finding Expandable Induced Cardiovascular Progenitor Cells |
| Q55229425 | Forging the Fate of Cellular Therapies for Cardiovascular Disease. |
| Q35221817 | Formation of human myocardium in the rat heart from human embryonic stem cells |
| Q50977973 | Functional and bioenergetic modulations in the infarct border zone following autologous mesenchymal stem cell transplantation. |
| Q35539690 | Functional and transcriptomic recovery of infarcted mouse myocardium treated with bone marrow mononuclear cells. |
| Q50648691 | Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture. |
| Q38000518 | Functional screening of intracardiac cell transplants using two-photon fluorescence microscopy. |
| Q51712826 | Fusion of circulating blood cells with solid-organ tissue cells in clinical stem cell transplants: a potential therapeutic model? |
| Q81424114 | G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes |
| Q37176449 | G-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction |
| Q36227832 | G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis |
| Q27003270 | GPCRs in stem cell function |
| Q39136745 | Generation of induced cardiac progenitor cells via somatic reprogramming |
| Q34298871 | Genetic Engineering of Mesenchymal Stem Cells and Its Application in Human Disease Therapy |
| Q37156670 | Genetic enhancement of stem cell engraftment, survival, and efficacy |
| Q37010620 | Genetic modification of stem cells for transplantation |
| Q30495127 | Germ plasm-like Dot cells maintain their wound regenerative function after in vitro expansion |
| Q36540656 | Getting to the heart of myocardial stem cells and cell therapy |
| Q38160044 | Global search for right cell type as a treatment modality for cardiovascular disease |
| Q53055138 | Granulocyte-colony stimulating factor reduces cardiomyocyte apoptosis and ameliorates diastolic dysfunction in Otsuka Long-Evans Tokushima Fatty rats. |
| Q28290417 | Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy |
| Q33781018 | Growth factors induce the improved cardiac remodeling in autologous mesenchymal stem cell-implanted failing rat hearts |
| Q36029669 | Healing a broken heart with stem cells |
| Q57395528 | Heart failure and regenerative cardiology |
| Q33605156 | Heart failure management: the present and the future |
| Q24562846 | Heart regeneration |
| Q38654054 | Heart regeneration and repair after myocardial infarction: translational opportunities for novel therapeutics |
| Q89870117 | Heart regeneration in mouse and human: A bioengineering perspective |
| Q34390677 | Heart regeneration: Past, present and future |
| Q36606663 | Heart repair and stem cells |
| Q98778973 | Hematopoietic Stem Cells and Mesenchymal Stromal Cells in Acute Radiation Syndrome |
| Q28072887 | Hematopoietic Stem Cells in Regenerative Medicine: Astray or on the Path? |
| Q37429871 | Hematopoietic stem and progenitor cells: their mobilization and homing to bone marrow and peripheral tissue |
| Q36824005 | Hematopoietic stem cells are pluripotent and not just "hematopoietic". |
| Q33235072 | Hematopoietic stem cells provide repair functions after laser-induced Bruch's membrane rupture model of choroidal neovascularization |
| Q37194059 | Hematopoietic stem cells: ex-vivo expansion and therapeutic potential for myocardial ischemia |
| Q39458079 | Hepatocyte growth factor-modified mesenchymal stem cells improve ischemia/reperfusion-induced acute lung injury in rats |
| Q45873033 | Hepatocyte growth factor-transfected skeletal myoblasts to limit the development of postinfarction heart failure |
| Q93120633 | Heterogeneity of Adult Cardiac Stem Cells |
| Q39777378 | High-resolution X-ray microtomography for three-dimensional imaging of cardiac progenitor cell homing in infarcted rat hearts |
| Q39596402 | Higher frequencies of BCRP+ cardiac resident cells in ischaemic human myocardium |
| Q37667562 | Human and murine very small embryonic-like cells represent multipotent tissue progenitors, in vitro and in vivo |
| Q36882814 | Human cardiospheres as a source of multipotent stem and progenitor cells |
| Q50525938 | Human cord blood CD34+ progenitor cells acquire functional cardiac properties through a cell fusion process. |
| Q35085099 | Human cord blood stem cells generate human cytokeratin 18-negative hepatocyte-like cells in injured mouse liver |
| Q36025653 | Human embryonic stem cell transplantation to repair the infarcted myocardium |
| Q36804578 | Human embryonic stem cell-derived cardiomyocytes: inducing strategies. |
| Q37911584 | Human embryonic stem cell-derived vascular smooth muscle cells in therapeutic neovascularisation |
| Q37023827 | Human embryonic stem cells and cardiac repair |
| Q40353752 | Human embryonic stem cells: towards therapies for cardiac disease. Derivation of a Dutch human embryonic stem cell line |
| Q37924272 | Human pluripotent stem cell-based approaches for myocardial repair: from the electrophysiological perspective |
| Q39847147 | Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents. |
| Q35874256 | Human stem cells shape the future of cardiac regeneration research |
| Q37262399 | Humanized large-scale expanded endothelial colony-forming cells function in vitro and in vivo. |
| Q37247304 | Hyaluronic acid-based hydrogel induces neovascularization and improves cardiac function in a rat model of myocardial infarction |
| Q46323076 | Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization |
| Q37363758 | IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction |
| Q50710399 | Identification of interventricular septum precursor cells in the mouse embryo. |
| Q36124315 | Identity deception: not a crime for a stem cell |
| Q37242779 | Imaging gene expression in human mesenchymal stem cells: from small to large animals |
| Q30494736 | Imaging survival and function of transplanted cardiac resident stem cells |
| Q35879474 | Immuno-modification of enhancing stem cells targeting for myocardial repair. |
| Q51714776 | Impact of different bone marrow cell preparations on left ventricular remodelling after experimental myocardial infarction. |
| Q39949483 | Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity |
| Q42548551 | Implantation of a three-dimensional fibroblast matrix improves left ventricular function and blood flow after acute myocardial infarction |
| Q33781650 | Improved mobilization of the CD34(+) and CD133(+) bone marrow-derived circulating progenitor cells by freshly isolated intracoronary bone marrow cell transplantation in patients with ischemic heart disease |
| Q35163294 | Improvement of cardiac function by placenta-derived mesenchymal stem cells does not require permanent engraftment and is independent of the insulin signaling pathway |
| Q31028296 | Improvement of cardiac function in mouse myocardial infarction after transplantation of epigenetically-modified bone marrow progenitor cells |
| Q33753521 | Improvement of myocardial perfusion reserve detected by cardiovascular magnetic resonance after direct endomyocardial implantation of autologous bone marrow cells in patients with severe coronary artery disease |
| Q28069954 | Improving the outcome of kidney transplantation by ameliorating renal ischemia reperfusion injury: lost in translation? |
| Q50518747 | In situ cardiomyogenic differentiation of implanted bone marrow mononuclear cells by local delivery of transforming growth factor-β1. |
| Q35855818 | In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. |
| Q35586384 | In vivo clonal analysis reveals lineage-restricted progenitor characteristics in mammalian kidney development, maintenance, and regeneration. |
| Q35621666 | In vivo functional and transcriptional profiling of bone marrow stem cells after transplantation into ischemic myocardium |
| Q37120197 | Increased cardiac myocyte progenitors in failing human hearts |
| Q38203865 | Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. |
| Q51743757 | Inflammatory responses after intracoronary mononuclear BM cell therapy in swine. |
| Q33433387 | Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy |
| Q37606016 | Innate regeneration in the aging heart: healing from within |
| Q35216066 | Intracardiac injection of matrigel induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model |
| Q33327638 | Intracoronary autologous bone marrow-derived mononuclear cell transplantation improves coronary collateral vessel formation and recruitment capacity in patients with ischemic cardiomyopathy: a combined hemodynamic and scintigraphic approach |
| Q34332467 | Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial |
| Q33505911 | Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial |
| Q34318046 | Intracoronary delivery of bone-marrow-derived stem cells |
| Q39836735 | Intramyocardial Peptide Nanofiber Injection Improves Postinfarction Ventricular Remodeling and Efficacy of Bone Marrow Cell Therapy in Pigs |
| Q34637607 | Intramyocardial transplantation and tracking of human mesenchymal stem cells in a novel intra-uterine pre-immune fetal sheep myocardial infarction model: a proof of concept study |
| Q33218591 | Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney |
| Q40191474 | Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis |
| Q44948306 | Is heart regeneration on the right track? |
| Q37408693 | Is stem cell-based therapy going on or out for cardiac disease? |
| Q42456173 | Ischaemia/reperfusion induced cardiac stem cell homing to the injured myocardium by stimulating stem cell factor expression via NF-kappaB pathway |
| Q39109413 | Ischemia/Reperfusion |
| Q36691627 | Isolation and expansion of resident cardiac progenitor cells. |
| Q38140885 | JAK-STAT signaling in cardiomyogenesis of cardiac stem cells |
| Q34042110 | Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury |
| Q34292542 | Label-free enrichment of functional cardiomyocytes using microfluidic deterministic lateral flow displacement |
| Q33949477 | Laser-guidance-based cell deposition microscope for heterotypic single-cell micropatterning |
| Q34090699 | LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction |
| Q37778540 | Lessons for cardiac regeneration and repair through development |
| Q51808978 | Liver repopulation trial using bone marrow cells in a retrorsine-induced chronic hepatocellular injury model. |
| Q37043528 | Logistics of stem cell isolation, preparation and delivery for heart repair: concerns of clinicians, manufacturers, investors and public health. |
| Q37305343 | Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up |
| Q41665176 | Lost and found: cardiac stem cell therapy revisited |
| Q59057872 | Lost in translation |
| Q37506545 | Lost in translation: what is limiting cardiomyoplasty and can tissue engineering help? |
| Q42409098 | Low connexin channel-dependent intercellular communication in human adult hematopoietic progenitor/stem cells: probing mechanisms of autologous stem cell therapy |
| Q34962330 | MSCs transplantation with application of G-CSF reduces apoptosis or increases VEGF in rabbit model of myocardial infarction |
| Q38262148 | Making it stick: chasing the optimal stem cells for cardiac regeneration. |
| Q93147053 | Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate |
| Q37198850 | Mesenchymal Stem Cells Reversed Morphine Tolerance and Opioid-induced Hyperalgesia |
| Q38069136 | Mesenchymal stem cells and kidney repair |
| Q41983710 | Mesenchymal stem cells are recruited to striated muscle by NFAT/IL-4-mediated cell fusion |
| Q36056155 | Mesenchymal stem cells for cardiac regeneration: translation to bedside reality |
| Q37884436 | Mesenchymal stem cells for cardiovascular regeneration |
| Q44592644 | Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation |
| Q35942343 | Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment |
| Q36508661 | Mesenchymal stem cells: potential application in intervertebral disc regeneration. |
| Q37296154 | Metabolic modulation and cellular therapy of cardiac dysfunction and failure |
| Q37191403 | Methods for studying stem cells: adult stem cells for lung repair |
| Q34807143 | Methods to assess stem cell lineage, fate and function |
| Q34907048 | Microarray-based characterization of a colony assay used to investigate endothelial progenitor cells and relevance to endothelial function in humans |
| Q36477618 | Minimally invasive cell-seeded biomaterial systems for injectable/epicardial implantation in ischemic heart disease |
| Q50516083 | Mobilization of bone marrow cells by CSF3 protects mice from bleomycin-induced lung injury. |
| Q39027005 | Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease |
| Q34125754 | Molecular imaging of bone marrow mononuclear cell survival and homing in murine peripheral artery disease |
| Q36416525 | Molecular imaging of cardiac stem cell transplantation |
| Q47363128 | Molecular medicine: the writing is on the vessel wall |
| Q37808269 | Molecular physiology of cardiac regeneration |
| Q50660744 | Monitoring of cell therapy and assessment of cardiac function using magnetic resonance imaging in a mouse model of myocardial infarction. |
| Q37122225 | Monocyte and macrophage heterogeneity in the heart |
| Q54217535 | Most of the Dust Has Settled: cKit+ Progenitor Cells Are an Irrelevant Source of Cardiac Myocytes In Vivo. |
| Q36225111 | Multiple stem cell populations contribute to the formation of the myocardium |
| Q63364496 | Multipotent Progenitor Cells in Regenerative Cardiovascular Medicine |
| Q42853310 | Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment |
| Q42407370 | Multipotent stem cells in cardiac regenerative therapy |
| Q28085334 | Multipotent stem cells of the heart-do they have therapeutic promise? |
| Q36659319 | Muscle-derived stem cell sheets support pump function and prevent cardiac arrhythmias in a model of chronic myocardial infarction. |
| Q37157338 | MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases |
| Q48247352 | Myocardial Regeneration via Progenitor Cell-Derived Exosomes |
| Q35727937 | Myocardial improvement with human embryonic stem cell-derived cardiomyocytes enriched by p38MAPK inhibition. |
| Q34402223 | Myocardial regeneration with bone-marrow-derived stem cells |
| Q36247746 | Myocardial regenerative properties of macrophage populations and stem cells. |
| Q35168352 | Myocardial remodeling: cellular and extracellular events and targets |
| Q37176440 | Myocardial repair: from salvage to tissue reconstruction |
| Q35778889 | Myocardial restoration: is it the cell or the architecture or both? |
| Q33635730 | Myocardial survival signaling in response to stem cell transplantation |
| Q37578552 | Myocardial tissue engineering: the quest for the ideal myocardial substitute |
| Q36304191 | Myocardial-cell replacement: the science, the clinic and the future |
| Q35733632 | Myocyte proliferation in the developing heart |
| Q88540277 | Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing |
| Q38074105 | Natural ECM as biomaterial for scaffold based cardiac regeneration using adult bone marrow derived stem cells. |
| Q39022829 | Natural killer cells in inflammatory heart disease. |
| Q36949077 | Neoangiogenesis with endothelial precursors for the treatment of ischemia |
| Q64102043 | Neural stem cell-derived small extracellular vesicles attenuate apoptosis and neuroinflammation after traumatic spinal cord injury by activating autophagy |
| Q79898170 | Neurological and functional recovery in human stroke are associated with peripheral blood CD34+ cell mobilization |
| Q28564350 | Neuropeptide y and neuropeptide y y5 receptor interaction restores impaired growth potential of aging bone marrow stromal cells |
| Q91944891 | Neutrophil extracellular traps and fibrocytes in ST-segment elevation myocardial infarction |
| Q57176905 | New Myocyte Formation in the Adult Heart: Endogenous Sources and Therapeutic Implications |
| Q28306609 | Non-canonical Wnt signaling enhances differentiation of human circulating progenitor cells to cardiomyogenic cells |
| Q36667418 | On experimental design and discourse in plasticity research |
| Q35841708 | On how Rac controls hematopoietic stem cell activity |
| Q30986046 | Optimization of targeted cell replacement therapy: a new approach for lung disease |
| Q38982831 | Optimizing stem cells for cardiac repair: Current status and new frontiers in regenerative cardiology |
| Q37997980 | Organ repair and regeneration: an overview. |
| Q27023325 | Origin of cardiomyocytes in the adult heart |
| Q36415354 | Overview of recent advances in molecular cardiology |
| Q51011615 | Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischaemic myocardium. |
| Q29620571 | Paracrine mechanisms in adult stem cell signaling and therapy |
| Q50528333 | Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart. |
| Q38376997 | Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function |
| Q28071643 | Peripheral blood mononuclear cell secretome for tissue repair |
| Q37467729 | Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). |
| Q46770537 | Phenotypic characteristics of hybrid cells produced by cell fusion of porcine adrenal chromaffin cells with human mesenchymal stem cells: a preliminary study |
| Q50773050 | Phenotypic characterization and preclinical production of human lineage-negative cells for regenerative stem cell therapy. |
| Q56777886 | Plasticity and cardiovascular applications of multipotent adult progenitor cells |
| Q35684656 | Plasticity of adult stem cells |
| Q36855438 | Pluripotent stem cells for cardiac regeneration: overview of recent advances & emerging trends |
| Q35185979 | Poor functional recovery after transplantation of diabetic bone marrow stem cells in ischemic myocardium |
| Q39069601 | Possible Muscle Repair in the Human Cardiovascular System |
| Q28306800 | Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages |
| Q36523923 | Potential of stem-cell-based therapies for heart disease |
| Q37382220 | Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue |
| Q37668953 | Pregenerative medicine: developmental paradigms in the biology of cardiovascular regeneration |
| Q50657450 | Pressure-induced cardiac overload induces upregulation of endothelial and myocardial progenitor cells. |
| Q37595834 | Progenitor cell therapy for heart disease |
| Q40457855 | Progenitor cell therapy of ischemic heart disease: the new frontier. |
| Q39266763 | Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy. |
| Q36108608 | Progenitor/stem cell transplantation for repair of myocardial infarction: Hype or hope? |
| Q26823933 | Programming and reprogramming a human heart cell |
| Q36327823 | Progress and prospects: cell based regenerative therapy for cardiovascular disease. |
| Q59086575 | Prometheus unbound |
| Q41214335 | Promises and pitfalls in cell replacement therapy for heart failure |
| Q94503644 | Promoting Cardiac Regeneration and Repair Using Acellular Biomaterials |
| Q38087578 | Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success |
| Q41296731 | Promoting effect of small molecules in cardiomyogenic and neurogenic differentiation of rat bone marrow-derived mesenchymal stem cells |
| Q30537131 | Prospective isolation of human embryonic stem cell-derived cardiovascular progenitors that integrate into human fetal heart tissue |
| Q38629150 | Proteomics of cell-cell interactions in health and disease. |
| Q54619692 | Purified human bone marrow multipotent mesenchymal stem cells regenerate infarcted myocardium in experimental rats. |
| Q33361149 | Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone |
| Q37444118 | Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction |
| Q35070251 | Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease |
| Q36312990 | Recent advances in primary percutaneous intervention for acute myocardial infarction |
| Q27687840 | Regenerating functional heart tissue for myocardial repair |
| Q36497191 | Regenerating new heart with stem cells |
| Q91691962 | Regenerating the field of cardiovascular cell therapy |
| Q22251075 | Regenerating the heart |
| Q36038854 | Regeneration of the heart |
| Q47744623 | Regenerative Stem Cell Therapy Optimization via Tissue Engineering in Heart Failure with Reduced Ejection Fraction |
| Q36462071 | Regenerative medicine for cardiovascular disorders-new milestones: adult stem cells |
| Q38075104 | Regenerative medicine for the treatment of heart disease |
| Q35222931 | Rejuvenation: an integrated approach to regenerative medicine |
| Q37104058 | Repairing damaged myocardium: evaluating cells used for cardiac regeneration |
| Q36406482 | Resident progenitors and bone marrow stem cells in myocardial renewal and repair |
| Q33865856 | Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells |
| Q53419687 | Retention of nanoparticles-labeled bone marrow mononuclear cells in the isolated ex vivo perfused heart after myocardial infarction in animal model. |
| Q37932621 | Retrograde delivery of stem cells: promising delivery strategy for myocardial regenerative therapy. |
| Q37766134 | Review of stem cell-based therapy for the treatment of cardiovascular disease |
| Q37976449 | Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells |
| Q91905110 | Role of Adult Tissue-Derived Pluripotent Stem Cells in Bone Regeneration |
| Q37689954 | Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation |
| Q36294424 | Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart |
| Q37687409 | Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy |
| Q36255973 | Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia. |
| Q38904719 | Roles of exosomes in cardioprotection |
| Q52731083 | SDF 1-alpha Attenuates Myocardial Injury Without Altering the Direct Contribution of Circulating Cells. |
| Q90362748 | STAT3 for Cardiac Regenerative Medicine: Involvement in Stem Cell Biology, Pathophysiology, and Bioengineering |
| Q34410872 | Safe genetic modification of cardiac stem cells using a site-specific integration technique |
| Q38220004 | Sca-1+ cardiac progenitor cells and heart-making: a critical synopsis. |
| Q80322388 | Searching for reputability: first randomised study on bone-marrow transplantation in the heart |
| Q35946601 | Sensitive detection of GFP utilizing tyramide signal amplification to overcome gene silencing |
| Q51632340 | Sex of muscle stem cells does not influence potency for cardiac cell therapy. |
| Q34827093 | Single cell gene profiling revealed heterogeneity of paracrine effects of bone marrow cells in mouse infarcted hearts |
| Q52729623 | Single-cell analysis of the fate of c-kit-positive bone marrow cells. |
| Q35945147 | Some notes on stem cell therapy in cardiovascular diseases |
| Q36426360 | Sources of cardiomyocytes for stem cell therapy: an update |
| Q48671598 | Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. |
| Q30275148 | Sphingosine-1-Phosphate Receptor-3 Supports Hematopoietic Stem and Progenitor Cell Residence Within the Bone Marrow Niche |
| Q50508243 | Splenectomy enhances the anti-fibrotic effect of bone marrow cell infusion and improves liver function in cirrhotic mice and patients. |
| Q53651473 | Statins impair survival of primary human mesenchymal progenitor cells via mevalonate depletion, NF-κB signaling, and Bnip3. |
| Q51067725 | Stem Cell Banking and Its Impact on Cardiac Regenerative Medicine. |
| Q28069300 | Stem Cell Therapy for the Heart: Blind Alley or Magic Bullet? |
| Q35125820 | Stem Cell Therapy in Acute Myocardial Infarction: A Pot of Gold or Pandora's Box. |
| Q39329517 | Stem Cell Therapy: A New Therapeutic Option for Cardiovascular Diseases. |
| Q37045472 | Stem cell differentiation: cardiac repair |
| Q34479264 | Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. |
| Q37991028 | Stem cell mediated cardiovascular repair |
| Q33708216 | Stem cell paracrine actions and tissue regeneration |
| Q36599286 | Stem cell recruitment after injury: lessons for regenerative medicine |
| Q38098219 | Stem cell stimulation of endogenous myocyte regeneration |
| Q37087315 | Stem cell therapies in cardiovascular disease A "realistic" appraisal. |
| Q34441749 | Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment |
| Q26801514 | Stem cell therapy and tissue engineering for correction of congenital heart disease |
| Q37827158 | Stem cell therapy for cardiac disease. |
| Q34129904 | Stem cell therapy for cardiac dysfunction |
| Q37544884 | Stem cell therapy for cardiac repair: benefits and barriers |
| Q37877423 | Stem cell therapy for heart diseases |
| Q40097837 | Stem cell therapy for heart failure: the science and current progress. |
| Q39850212 | Stem cell therapy for ischemic heart disease |
| Q36529988 | Stem cell therapy for ischemic heart disease: beginning or end of the road? |
| Q35980614 | Stem cell therapy for the heart |
| Q57789111 | Stem cell therapy for treating osteonecrosis of the femoral head: From clinical applications to related basic research |
| Q37070968 | Stem cell therapy in acute myocardial infarction |
| Q35087066 | Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease |
| Q38225999 | Stem cell therapy: challenges ahead |
| Q43668158 | Stem cell tourism and the power of hope |
| Q36368239 | Stem cell transplantation for the treatment of myocardial infarction |
| Q34315088 | Stem cell treatment of the heart: a review of its current status on the brink of clinical experimentation |
| Q35128063 | Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation |
| Q38050281 | Stem cell-based therapy for ischemic heart disease. |
| Q51726662 | Stem cell-derived cardiomyocytes after bone marrow and heart transplantation. |
| Q37293765 | Stem cell-mediated natural tissue engineering |
| Q36228883 | Stem cells |
| Q36842866 | Stem cells and cardiac regeneration |
| Q37766151 | Stem cells and cardiac repair: a critical analysis |
| Q35910261 | Stem cells and muscle diseases. |
| Q37991771 | Stem cells and regenerative medicine - future perspectives |
| Q35832759 | Stem cells and repair of the heart. |
| Q36428648 | Stem cells and their potential relevance to paediatric cardiology |
| Q38072245 | Stem cells and their role in renal ischaemia reperfusion injury |
| Q36124846 | Stem cells as future therapy in cardiology |
| Q36225214 | Stem cells for cardiomyocyte regeneration: state of the art. |
| Q37261623 | Stem cells for heart cell therapies |
| Q36446920 | Stem cells for the ischaemic heart |
| Q33863225 | Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function |
| Q37183624 | Stem cells in the heart: what's the buzz all about? Part 2: Arrhythmic risks and clinical studies. |
| Q29614416 | Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming |
| Q47717967 | Stem cells: Aging and transcriptional fingerprints |
| Q36254634 | Stem cells: From embryology to cellular therapy? An appraisal of the present state of art. |
| Q38467240 | Stem-cell angiogenesis and regeneration of the heart: review of a saga of 2 decades. |
| Q37089732 | Stem-cell therapy for cardiac disease |
| Q37164041 | Stem-cell-based therapy and lessons from the heart |
| Q37255265 | Stemming heart failure with cardiac- or reprogrammed-stem cells |
| Q46935022 | Stereological and histological analysis of the developing rat heart |
| Q34372277 | Stimulation of endogenous cardioblasts by exogenous cell therapy after myocardial infarction |
| Q34795299 | Strategies for cardiac regeneration and repair |
| Q36380582 | Strategies for developing therapeutic application of human embryonic stem cells. |
| Q27315347 | Stroma cell-derived factor-1α signaling enhances calcium transients and beating frequency in rat neonatal cardiomyocytes |
| Q37345060 | Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction |
| Q52598364 | Systemic signals regulate ageing and rejuvenation of blood stem cell niches. |
| Q36642702 | Targeting angiogenesis versus myogenesis with cardiac cell therapy |
| Q37220758 | Targeting human CD34+ hematopoietic stem cells with anti-CD45 x anti-myosin light-chain bispecific antibody preserves cardiac function in myocardial infarction |
| Q38234910 | Targeting pleiotropic signaling pathways to control adult cardiac stem cell fate and function. |
| Q47862843 | Telomere-independent cellular senescence in human fetal cardiomyocytes |
| Q37776212 | Teratomas from pluripotent stem cells: A clinical hurdle |
| Q35558497 | Terminal differentiation is not a major determinant for the success of stem cell therapy - cross-talk between muscle-derived stem cells and host cells |
| Q39067173 | The ATP-Binding Cassette Transporter BCRP1/ABCG2 Plays a Pivotal Role in Cardiac Repair After Myocardial Infarction Via Modulation of Microvascular Endothelial Cell Survival and Function |
| Q38535126 | The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy |
| Q39095681 | The Elusive Progenitor Cell in Cardiac Regeneration: Slip Slidin' Away |
| Q38746402 | The Heart and Great Vessels |
| Q58106677 | The Language of Hope: Therapeutic Intent in Stem-Cell Clinical Trials |
| Q42334472 | The Neuroprotective Effects of Muscle-Derived Stem Cells via Brain-Derived Neurotrophic Factor in Spinal Cord Injury Model |
| Q58771019 | The Potential of Stem Cells and Stem Cell-Derived Exosomes in Treating Cardiovascular Diseases |
| Q58998678 | The Systems Biology of Stem Cell Released Molecules—Based Therapeutics |
| Q61443241 | The biochemical and electrophysiological profiles of amniotic fluid-derived stem cells following Wnt signaling modulation cardiac differentiation |
| Q36174197 | The bone marrow--cardiac axis of myocardial regeneration |
| Q38081827 | The cellular memory disc of reprogrammed cells |
| Q34026411 | The combination of angiotensin II and 5-azacytidine promotes cardiomyocyte differentiation of rat bone marrow mesenchymal stem cells |
| Q89661677 | The effect of preconditioning with high-intensity training on tissue levels of G-CSF, its receptor and C-kit after an acute myocardial infarction in male rats |
| Q26746647 | The emerging role of viral vectors as vehicles for DMD gene editing |
| Q37625460 | The existence of myocardial repair: mechanistic insights and enhancements |
| Q37790961 | The future of regenerating the myocardium |
| Q36596455 | The future of therapeutic myocardial angiogenesis |
| Q35092172 | The heterogeneous murine corneal stromal cell populations in vitro. |
| Q37096652 | The immune system and cardiac repair. |
| Q64914852 | The march of pluripotent stem cells in cardiovascular regenerative medicine. |
| Q37839779 | The origin of interstitial myofibroblasts in chronic kidney disease |
| Q33991630 | The peripheral chimerism of bone marrow-derived stem cells after transplantation: regeneration of gastrointestinal tissues in lethally irradiated mice |
| Q36776231 | The promise and perils of stem cell therapeutics |
| Q80507346 | The regenerative potential of the human heart |
| Q38006725 | The renin-angiotensin system, bone marrow and progenitor cells |
| Q36275663 | The role of circulating precursors in vascular repair and lesion formation. |
| Q37306210 | The role of progenitor cells in the development of intimal hyperplasia |
| Q34405511 | The role of stem cells in cardiac regeneration. |
| Q37067647 | The role of stem cells in the post-MI patient |
| Q35874253 | The strength of plasticity: stem cells for cardiac repair |
| Q37053163 | The therapeutic potential of stem cells in heart disease |
| Q42231598 | The transplantation of Akt-overexpressing amniotic fluid-derived mesenchymal stem cells protects the heart against ischemia-reperfusion injury in rabbits |
| Q51167242 | The use of extracellular matrix as an inductive scaffold for the partial replacement of functional myocardium. |
| Q39580194 | The use of stem cells for the repair of cardiac tissue in ischemic heart disease |
| Q36406459 | The utility of magnetic resonance imaging in cardiac tissue regeneration trials |
| Q47763374 | Therapeutic Potential of Hematopoietic Stem Cell-Derived Exosomes in Cardiovascular Disease. |
| Q37608469 | Therapeutic angiogenesis for coronary artery disease: clinical trials of proteins, plasmids, adenovirus and stem cells |
| Q81140463 | Therapeutic angiogenesis gains a leg to stand on |
| Q36847077 | Therapeutic angiogenesis with bone marrow--derived stem cells |
| Q36395705 | Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair |
| Q36909360 | Therapeutic potential of adult progenitor cells in cardiovascular disease |
| Q42121480 | Therapeutic potential of human adipose stem cells in a rat myocardial infarction model |
| Q28295270 | Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair |
| Q38013063 | Thymosin β4 and cardiac regeneration: are we missing a beat? |
| Q28650181 | Time to do something about reproducibility |
| Q30888146 | Timing of bone marrow cell delivery has minimal effects on cell viability and cardiac recovery after myocardial infarction |
| Q40199212 | Tissue engineering approaches for the development of a contractile cardiac patch. |
| Q51094994 | Tissue engineering using adult stem cells. |
| Q41672067 | Tissue inhibitor of matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal stem cells enhances cell therapy after myocardial infarction |
| Q33537670 | Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling |
| Q29394460 | Towards regenerative therapy for cardiac disease |
| Q37946759 | Towards the generation of patient-specific patches for cardiac repair. |
| Q27438164 | Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes |
| Q40334464 | Transcriptional profiling of reporter genes used for molecular imaging of embryonic stem cell transplantation |
| Q37285238 | Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells |
| Q26860340 | Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement |
| Q35995055 | Translational aspects of cardiac cell therapy |
| Q81228975 | Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study |
| Q44828167 | Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction |
| Q37625948 | Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. |
| Q50747193 | Treatment with granulocyte colony-stimulating factor ameliorates chronic heart failure. |
| Q59091693 | US government halts heart stem-cell study |
| Q36438947 | Ultrastructural evidence of exosome secretion by progenitor cells in adult mouse myocardium and adult human cardiospheres |
| Q61479658 | Umbilical Cord Blood-Derived Stem Cells Spontaneously Express Cardiomyogenic Traits |
| Q50664911 | Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. |
| Q33683767 | Unchain my heart: the scientific foundations of cardiac repair |
| Q57823657 | Undeniable Evidence That the Adult Mammalian Heart Lacks an Endogenous Regenerative Stem Cell |
| Q36126866 | Update on the use of stem cells for cardiac disease |
| Q39926156 | Use of ferumoxides for stem cell labeling |
| Q24616111 | Use of the parabiotic model in studies of cutaneous wound healing to define the participation of circulating cells |
| Q38121727 | Vascular endothelial growth factor in heart failure |
| Q45127736 | Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo |
| Q47589451 | Wideband high-frequency echocardiography to evaluate myocardial infarct size |
| Q83144947 | [Embryonic stem cells. Future perspectives] |
| Q53608261 | [Future perspectives in the treatment of heart failure: from cell transplantation to cardiac regeneration]. |
| Q80260743 | [Investigation in stem cells] |
| Q81567481 | [Regenerative medicine with adult stem cells] |
| Q83009574 | [Stem cells treatment for patients with heart diseases] |
| Q36484631 | beta(1)- and beta(2)-adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non-failing adult human heart |
| Q34004496 | c-Kit+ bone marrow stem cells differentiate into functional cardiac myocytes. |
| Q46798182 | c-kit(+) cells adopt vascular endothelial but not epithelial cell fates during lung maintenance and repair. |
| Q34021586 | c-kit+ cells minimally contribute cardiomyocytes to the heart |
| Q27315833 | c-kitpos GATA-4 high rat cardiac stem cells foster adult cardiomyocyte survival through IGF-1 paracrine signalling |
Search more.